In addition, treatment with the DPP4 inhibitor sitagliptin after surgery for colorectal or lung cancer in patients with diabetes was associated with greater overall survival than treatment with other diabetic medications [18], suggesting that sCD26/DPP4 may have a role in regulating anti-tumor activity. Here, DPP4 is linked to lung carcinoma.